Verve Therapeutics vs Pliant Therapeutics

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pliant Therapeutics leads in AI visibility (62 vs 20)
Verve Therapeutics logo

Verve Therapeutics

EmergingBiotechnology

Cardiovascular Gene Editing

Verve Therapeutics develops single-course gene editing medicines for cardiovascular disease, aiming to permanently lower LDL cholesterol with one treatment.

AI VisibilityBeta
Overall Score
D20
Category Rank
#1 of 1
AI Consensus
67%
Trend
up
Per Platform
ChatGPT
19
Perplexity
19
Gemini
26

About

Verve Therapeutics is a clinical-stage genetic medicines company founded in 2018 by Andrew Bellinger and Sekar Kathiresan, focused exclusively on using base editing to treat cardiovascular disease. The company is developing one-time treatments that permanently lower LDL cholesterol and triglycerides by editing genes in liver cells that regulate lipid metabolism, including PCSK9 and ANGPTL3. Verve's approach targets the root cause of common cardiovascular disease rather than requiring lifelong daily medication, with the goal of a single infusion delivering durable benefit. The lead program VERVE-101 targets PCSK9 in liver cells and has entered Phase 1b clinical trials, with early data showing substantial and durable LDL reductions in patients with heterozygous familial hypercholesterolemia. Verve is publicly traded on Nasdaq and has established partnerships with Vertex Pharmaceuticals to advance the cardiovascular base editing pipeline. The company represents a fundamentally new approach to preventing heart attacks and strokes at the genetic level.

Full profile
Pliant Therapeutics logo

Pliant Therapeutics

ChallengerBioTech

Fibrotic Disease

Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.

AI VisibilityBeta
Overall Score
B62
Category Rank
#1 of 1
AI Consensus
62%
Trend
up
Per Platform
ChatGPT
54
Perplexity
60
Gemini
55

About

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.

Full profile

AI Visibility Head-to-Head

20
Overall Score
62
#1
Category Rank
#1
67
AI Consensus
62
up
Trend
up
19
ChatGPT
54
19
Perplexity
60
26
Gemini
55
19
Claude
64
31
Grok
69

Key Details

Category
Cardiovascular Gene Editing
Fibrotic Disease
Tier
Emerging
Challenger
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Verve Therapeutics
Cardiovascular Gene Editing
Only Pliant Therapeutics
Fibrotic Disease

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.